Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist - Related Studies

Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist

This study has been completed.

Study NCT00001475. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Acquired Immunodeficiency Syndrome
		HIV Infection

2	Additional conditions recognized in this trial
		Communicable Diseases
		HIV Infections
		Immunologic Deficiency Syndromes
		Infection
		Syndrome

3	More general conditions related to this trial
		Disease
		Immune System Diseases
		Lentivirus Infections
		Pathologic Processes
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		IL-2 plus Anti-TNF or Thalidomide

5	Additional drug interventions recognized in this trial
		Interleukin-2
		Thalidomide

6	More general drug interventions related to this trial
		Analgesics
		Analgesics, Non-Narcotic
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Anti-Bacterial Agents
		Anti-Infective Agents
		Antineoplastic Agents
		Central Nervous System Agents
		Growth Inhibitors
		Growth Substances
		Immunologic Factors
		Immunosuppressive Agents
		Leprostatic Agents
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Sensory System Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		National Institute of Allergy and Infectious Diseases (NIAID)